Results 71 to 80 of about 366,991 (303)

miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. [PDF]

, 2015
MicroRNAs (miRNAs), a class of small non-coding RNAs, mediate gene expression by either cleaving target mRNAs or inhibiting their translation. They have key roles in the tumorigenesis of several cancers, including non-small cell lung cancer (NSCLC).
Cao, Yan, Huang, Pu-wen, Lou, Jian-fang, Pan, Shi-yang, Rao, Jian-yu, Shi, Xin-hui, Sun, Rui-hong, Wang, Fang, Wang, Hong, Wang, Peng, Xie, Er-fu, Xu, Jian, Xu, Ting   +12 more
core   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Synthesis of Self-Assembled Nanostructured Cisplatin Using the RESS Process

Pharmaceutics
Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability.
Sudhir Kumar Sharma, Loganathan Palanikumar, Renu Pasricha, Thirumurugan Prakasam, Mazin Magzoub, Ramesh Jagannathan   +5 more
doaj   +1 more source

Cellular Responses to Cisplatin-Induced DNA Damage

Journal of Nucleic Acids, 2010
Cisplatin is one of the most effective anticancer agents widely used in the treatment of solid tumors. It is generally considered as a cytotoxic drug which kills cancer cells by damaging DNA and inhibiting DNA synthesis.
Alakananda Basu, Soumya Krishnamurthy
doaj   +1 more source

Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. [PDF]

PLoS ONE, 2011
Cisplatin is a potent anticancer drug, but its clinical application has been limited due to its undesirable physicochemical characteristics and severe side effects.
Lihua Cheng, Chengmeng Jin, Wen Lv, Qiuping Ding, Xu Han   +4 more
doaj   +1 more source

European mtDNA Variants Are Associated With Differential Responses to Cisplatin, an Anticancer Drug: Implications for Drug Resistance and Side Effects. [PDF]

, 2019
Background: Cisplatin, a powerful antitumor agent, causes formation of DNA adducts, and activation of apoptotic pathways. Presently, cisplatin resistance develops in up to 70% of patients but the underlying molecular mechanism(s) are unclear and there ...
Abedi, Sina, Atilano, Shari R, Bota, Daniela, Chang, Steven, Chwa, Marilyn, Jazwinski, S Michal, Kenney, M Cristina, Liu, Catherine, Lu, Stephanie, Miceli, Michael V, Norman, Lucas, Patel, Tej H, Thaker, Kunal, Udar, Nitin   +13 more
core   +1 more source

A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]

, 2016
Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis, F. Y. Coxon, J. S. Graham, K. Boyd, L. R. Wall, M. Highley, M. M. Eatock, P. Bützberger-Zimmerli, S. Harden, T. R. J. Evans, T. S. Maughan   +10 more
core   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. [PDF]

, 2014
BackgroundIn 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of ...
A Kumari, AS Yang, C Festuccia, C Zeller, CA Stidley, CJ Piyathilake, D Ma, D Matei, D Shang, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DW Shen, E Gordian, E San Jose-Eneriz, EA Braga, F Crea, F Fang, H Iwata, H Kantarjian, H Kroeger, HM Kantarjian, J Charlet, J Shia, JA Plumb, JP Issa, JP Issa, JS Kim, K Ghoshal, K Onda, K Ramachandran, K Tikoo, KY Tse, L Ding, L Rothem, MA Kane, ML Orta, NH Nabilsi, R Zhao, RH Finnell, S Fu, S Vijayaraghavalu, SB Baylin, SS Muerkoster, T Tanaka, TB Lee, VF Chekhun, X Chang, XJ Liang, Y Li, Y Oki, Y Zhang, ZG Liu   +55 more
core   +2 more sources

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source